Candel Therapeutics (CADL) Long-Term Debt Repayments (2024 - 2025)

Candel Therapeutics (CADL) posted Long-Term Debt Repayments of -$4.2 million for Q4 2025, down 69.32% sequentially from -$2.5 million in Q3 2025, and down 69.32% YoY from -$13.8 million in Q4 2024.

Candel Therapeutics (CADL) Long-Term Debt Repayments (2024 - 2025) Analysis & Trends

Candel Therapeutics has reported Long-Term Debt Repayments for 2 years, with the latest figure at -$4.2 million in Q4 2025.

  • Quarterly Long-Term Debt Repayments fell 69.32% year-over-year to -$4.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.7 million (down 27.99% YoY) and the FY2025 annual result came in at -$11.7 million, down 27.99% from the prior year.
  • Long-Term Debt Repayments retreated to -$4.2 million in Q4 2025 per CADL's latest filing, from -$2.5 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at -$1.7 million in Q1 2024 and troughed at -$4.2 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 17.05 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Candel Therapeutics 643.41 Mn 643.41 Mn - -4.23 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -4.23 Mn
Dec 31, 2025 -4.23 Mn
Sep 30, 2025 -2.50 Mn
Sep 30, 2025 -2.50 Mn
Jun 30, 2025 -2.50 Mn
Jun 30, 2025 -2.50 Mn
Mar 31, 2025 -2.50 Mn
Mar 31, 2025 -2.50 Mn
Dec 31, 2024 -2.50 Mn
Dec 31, 2024 -2.50 Mn
Sep 30, 2024 -2.50 Mn
Sep 30, 2024 -2.50 Mn
Jun 30, 2024 -2.50 Mn
Jun 30, 2024 -2.50 Mn
Mar 31, 2024 -1.67 Mn
Mar 31, 2024 -1.67 Mn